{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:43:38Z","timestamp":1761561818334},"reference-count":37,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.jns.2013.11.031","type":"journal-article","created":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T08:50:13Z","timestamp":1385887813000},"page":"119-122","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["JCV epidemiology in MS (JEMS)\u2014Epidemiology of anti-JCV antibody prevalence in multiple sclerosis patients\u2014Portuguese data"],"prefix":"10.1016","volume":"337","author":[{"given":"Ana Martins","family":"da Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Ernestina","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jns.2013.11.031_bb0005","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/brain\/112.1.133","article-title":"The natural history of multiple sclerosis: a geographically based study","volume":"112","author":"Weinshenker","year":"1989","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.jns.2013.11.031_bb0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1017\/S0317167100047351","article-title":"Epidemiology of multiple sclerosis: a critical overview","volume":"20","author":"Sadovnick","year":"1993","journal-title":"Can J Neurol Sci"},{"isbn-type":"print","year":"2008","series-title":"Atlas multiple sclerosis resources in the world 2008","key":"10.1016\/j.jns.2013.11.031_bb0015","ISBN":"http:\/\/id.crossref.org\/isbn\/9789241563758"},{"issue":"4","key":"10.1016\/j.jns.2013.11.031_bb0020","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000337534","article-title":"Capture\u2013recapture as a potentially useful procedure for assessing prevalence of multiple sclerosis: methodologic exercise using Portuguese data","volume":"38","author":"de Sa","year":"2012","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.jns.2013.11.031_bb0025","unstructured":"Sa\u00fade DGd. 2007."},{"issue":"3","key":"10.1016\/j.jns.2013.11.031_bb0030","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1590\/S0004-282X2011000400024","article-title":"Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works","volume":"69","author":"Mendes","year":"2011","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.jns.2013.11.031_bb0035","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/157341311794480318","article-title":"Etiopathogenesis, classical immunotherapy and innovative nanotherapeutics for inflammatory neurological disorders","volume":"7","author":"S\u00e1","year":"2011","journal-title":"Curr Nanosci"},{"year":"2012","series-title":"Summary of product characteristics\u2014Tysabri","key":"10.1016\/j.jns.2013.11.031_bb0040"},{"issue":"9","key":"10.1016\/j.jns.2013.11.031_bb0045","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jns.2013.11.031_bb0050","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jns.2013.11.031_bb0055","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jns.2013.11.031_bb0060","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s11481-010-9203-1","article-title":"Molecular regulation of JC virus tropism: insights into potential therapeutic targets for progressive multifocal leukoencephalopathy","volume":"5","author":"Marshall","year":"2010","journal-title":"J Neuroimmune Pharmacol"},{"issue":"8","key":"10.1016\/j.jns.2013.11.031_bb0065","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","article-title":"Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project","volume":"10","author":"Carson","year":"2009","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.jns.2013.11.031_bb0070","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2217\/fvl.10.12","article-title":"JC virus-induced progressive multifocal leukoencephalopathy","volume":"5","author":"Saribas","year":"2010","journal-title":"Future Virol"},{"issue":"4","key":"10.1016\/j.jns.2013.11.031_bb0075","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.jns.2013.11.031_bb0080","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/infdis\/jir198","article-title":"Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity","volume":"204","author":"Gorelik","year":"2011","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.jns.2013.11.031_bb0085","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jns.2013.11.031_bb0090","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"issue":"Pt 7","key":"10.1016\/j.jns.2013.11.031_bb0095","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1099\/vir.0.020115-0","article-title":"Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians","volume":"91","author":"Antonsson","year":"2010","journal-title":"J Gen Virol"},{"issue":"6","key":"10.1016\/j.jns.2013.11.031_bb0100","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/597126","article-title":"Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors","volume":"199","author":"Egli","year":"2009","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.jns.2013.11.031_bb0105","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/ijc.21277","article-title":"Antibodies to JC and BK viruses among persons with non-Hodgkin lymphoma","volume":"117","author":"Engels","year":"2005","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.jns.2013.11.031_bb0110","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/jmv.21493","article-title":"Investigation of pre-diagnostic virological markers for progressive multifocal leukoencephalopathy in human immunodeficiency virus-infected patients","volume":"81","author":"Grabowski","year":"2009","journal-title":"J Med Virol"},{"issue":"3","key":"10.1016\/j.jns.2013.11.031_bb0115","doi-asserted-by":"crossref","first-page":"e1000363","DOI":"10.1371\/journal.ppat.1000363","article-title":"Seroepidemiology of human polyomaviruses","volume":"5","author":"Kean","year":"2009","journal-title":"PLoS Pathog"},{"issue":"1","key":"10.1016\/j.jns.2013.11.031_bb0120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0166-0934(03)00043-0","article-title":"Comparison of cell culture-grown JC virus (primary human fetal glial cells and the JCI cell line) and recombinant JCV VP1 as antigen for the detection of anti-JCV antibody by haemagglutination inhibition","volume":"109","author":"Knowles","year":"2003","journal-title":"J Virol Methods"},{"issue":"3","key":"10.1016\/j.jns.2013.11.031_bb0125","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/jmv.21710","article-title":"Characterization of JC human polyomavirus infection in a Portuguese population","volume":"82","author":"Matos","year":"2010","journal-title":"J Med Virol"},{"issue":"4","key":"10.1016\/j.jns.2013.11.031_bb0130","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/infdis\/127.4.467","article-title":"Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy","volume":"127","author":"Padgett","year":"1973","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.jns.2013.11.031_bb0135","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1158\/1055-9965.EPI-05-0728","article-title":"Prediagnostic circulating antibodies to JC and BK human polyomaviruses and risk of non-Hodgkin lymphoma","volume":"15","author":"Rollison","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"10.1016\/j.jns.2013.11.031_bb0140","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/ana.22137","article-title":"JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab","volume":"68","author":"Ryschkewitsch","year":"2010","journal-title":"Ann Neurol"},{"issue":"Pt 6","key":"10.1016\/j.jns.2013.11.031_bb0145","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1099\/vir.0.18842-0","article-title":"Seroepidemiology of the human polyomaviruses","volume":"84","author":"Stolt","year":"2003","journal-title":"J Gen Virol"},{"issue":"10","key":"10.1016\/j.jns.2013.11.031_bb0150","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/gut.2007.145698","article-title":"JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?","volume":"57","author":"Verbeeck","year":"2008","journal-title":"Gut"},{"issue":"Suppl. 4","key":"10.1016\/j.jns.2013.11.031_bb0155","first-page":"S451","article-title":"Prevalence of anti-JCV antibodies in MS patients receiving or considering treatment with natalizumab: baseline results of STRATIFY-1","volume":"76","author":"Bozic","year":"2011","journal-title":"Neurology"},{"issue":"S4","key":"10.1016\/j.jns.2013.11.031_bb0160","first-page":"371","article-title":"Anti-JC virus antibody prevalence in the JCV epidemiology in MS trial","volume":"18","author":"Bozic","year":"2012","journal-title":"Mult Scler"},{"issue":"10","key":"10.1016\/j.jns.2013.11.031_bb0170","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1086\/374739","article-title":"The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study","volume":"187","author":"Ling","year":"2003","journal-title":"J Infect Dis"},{"issue":"Suppl. 4","key":"10.1016\/j.jns.2013.11.031_bb0175","first-page":"A248","article-title":"Risk stratification for progressive multifocal leukoencephalopathy (PML) in MS patients: role of prior immunosuppressant use, natalizumab treatment duration, and anti-JCV antibody status","volume":"76","author":"Sandrock","year":"2011","journal-title":"Neurology"},{"issue":"Suppl. 10","key":"10.1016\/j.jns.2013.11.031_bb0180","article-title":"Contribution of natalizumab treatment duration, prior immunosuppressant use, and anti-JC virus antibody status to the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis-patients","volume":"17","author":"Bloomgren","year":"2011","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.jns.2013.11.031_bb0185","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1352458511435105","article-title":"Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab","volume":"18","author":"Sorensen","year":"2012","journal-title":"Mult Scler"},{"year":"2010","series-title":"Package insert","author":"Tysabri (natalizumab)","key":"10.1016\/j.jns.2013.11.031_bb0190"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X13030608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X13030608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T12:21:29Z","timestamp":1539001289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X13030608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":37,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0022510X13030608"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2013.11.031","relation":{},"ISSN":["0022-510X"],"issn-type":[{"type":"print","value":"0022-510X"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JCV epidemiology in MS (JEMS)\u2014Epidemiology of anti-JCV antibody prevalence in multiple sclerosis patients\u2014Portuguese data","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2013.11.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}